Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention-Reference-Cited by-同舟云学术

Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention

Published:2022-10 Issue:10 Volume:31 Page:106742
ISSN:1052-3057
Container-title:Journal of Stroke and Cerebrovascular Diseases
language:en
Short-container-title:Journal of Stroke and Cerebrovascular Diseases

Author:

Sharma Mukul,Molina Carlos A.,Toyoda Kazunori,Bereczki Daniel,Kasner Scott E.,Lutsep Helmi L.,Tsivgoulis Georgios,Ntaios George,Czlonkowska Anna,Shuaib Ashfaq,Amarenco Pierre,Endres Matthias,Diener Hans Christoph,Gailani David,Kahl Anja,Donovan Mark,Perera Vidya,Li Danshi,Hankey Graeme J.

Funder

Janssen Research and Development LLC

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Neurology (clinical),Rehabilitation,Surgery

Reference35 articles.

1. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA;Johnston;N Engl J Med,2018

2. Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile;Xu;Ann Neurol,2019

3. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA;Wang;N Engl J Med,2021

4. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA;Johnston;N Engl J Med,2020

5. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial;Toyoda;Lancet Neurol,2019

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Milvexian: An Oral, Bioavailable Factor XIa Inhibitor;Cardiology and Therapy;2024-08-17

2. Factor XIa inhibition as a therapeutic strategy for atherothrombosis;Journal of Thrombosis and Thrombolysis;2024-07-29

3. Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants;Scientific Reports;2024-07-18

4. Mechanisms of Hypercoagulability Driving Stroke Risk in Obesity;Neurology;2024-07-09

5. The current landscape of factor XI inhibitors;Thrombosis Update;2024-06